ATE285770T1 - Verfahren zur herstellung von carbapenem- antibiotika zubereitungen - Google Patents

Verfahren zur herstellung von carbapenem- antibiotika zubereitungen

Info

Publication number
ATE285770T1
ATE285770T1 AT00974020T AT00974020T ATE285770T1 AT E285770 T1 ATE285770 T1 AT E285770T1 AT 00974020 T AT00974020 T AT 00974020T AT 00974020 T AT00974020 T AT 00974020T AT E285770 T1 ATE285770 T1 AT E285770T1
Authority
AT
Austria
Prior art keywords
carbapenem
carbapenem antibiotic
antibiotic preparations
producing carbapenem
formulation
Prior art date
Application number
AT00974020T
Other languages
English (en)
Inventor
Anthony Al-Dehneh
William A Hunke
Kathleen J Illig
Anand Kanike
Hiren Patel
Scott D Reynolds
Stelios C Tsinontides
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE285770T1 publication Critical patent/ATE285770T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/02—Preparation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
AT00974020T 1999-10-29 2000-10-27 Verfahren zur herstellung von carbapenem- antibiotika zubereitungen ATE285770T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16248299P 1999-10-29 1999-10-29
PCT/US2000/029869 WO2001032172A1 (en) 1999-10-29 2000-10-27 Process for formulation of carbapenem antibiotic compositions

Publications (1)

Publication Number Publication Date
ATE285770T1 true ATE285770T1 (de) 2005-01-15

Family

ID=22585803

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00974020T ATE285770T1 (de) 1999-10-29 2000-10-27 Verfahren zur herstellung von carbapenem- antibiotika zubereitungen

Country Status (8)

Country Link
EP (1) EP1244444B1 (de)
JP (1) JP4854899B2 (de)
AT (1) ATE285770T1 (de)
AU (1) AU770165B2 (de)
CA (1) CA2388163C (de)
DE (1) DE60017194T2 (de)
ES (1) ES2234689T3 (de)
WO (1) WO2001032172A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548492B1 (en) * 1999-10-29 2003-04-15 Merck & Co., Inc. Process for formulation of carbapenem antibiotic compositions
EP1469886B8 (de) * 2002-02-01 2008-01-09 Shimoda Biotech (PTY) LTD Lyophilisierte pharmazeutische zusammensetzung von propofol
EP2505190A1 (de) * 2008-06-11 2012-10-03 Ranbaxy Laboratories Limited Polymorphe Form eines Ertapenem-Mononatriums und dessen Herstellungsprozess
US8691803B2 (en) * 2011-01-24 2014-04-08 Savior Lifetec Corporation Process for the preparation of antibiotic compounds
CA2910421A1 (en) 2013-05-07 2014-11-13 Mcmaster University Inhibitors of metallo-.beta.-lactamase-enzymes
KR101587420B1 (ko) * 2014-08-20 2016-01-22 주식회사 대웅제약 에르타페넴-함유 동결건조제제의 제조방법
KR20170014842A (ko) 2015-07-31 2017-02-08 주식회사 대웅제약 개선된 에르타페넴 주사제의 제조방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA62920C2 (en) * 1996-05-28 2004-01-15 Merck & Co Inc Carbapeneme antibiotic, a composition and a method for the preparation
HRP970281B1 (en) * 1996-05-28 2002-04-30 Merck & Co Inc Carbapenem antibiotic, composition and method of preparation
US6297231B1 (en) * 1996-10-28 2001-10-02 Merck & Co., Inc. Stabilized carbapenem antibiotic compositions and method of making
CA2268820A1 (en) * 1996-10-28 1998-05-07 Merck & Co., Inc. Stabilized carbapenem antibiotic compositions and method of making
CN1105719C (zh) * 1997-06-16 2003-04-16 麦克公司 稳定化碳青霉烯中间体及其合成用途

Also Published As

Publication number Publication date
CA2388163C (en) 2009-08-25
JP4854899B2 (ja) 2012-01-18
EP1244444A1 (de) 2002-10-02
EP1244444A4 (de) 2003-05-21
ES2234689T3 (es) 2005-07-01
CA2388163A1 (en) 2001-05-10
AU770165B2 (en) 2004-02-12
DE60017194D1 (de) 2005-02-03
DE60017194T2 (de) 2005-12-22
EP1244444B1 (de) 2004-12-29
WO2001032172A1 (en) 2001-05-10
JP2003514779A (ja) 2003-04-22
AU1245601A (en) 2001-05-14

Similar Documents

Publication Publication Date Title
NO166448C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazolidindioner.
ATE378341T1 (de) Verfahren zur formulierung antibiotischer verbindungen
BR0207294A (pt) Composto, processo para a preparação de um composto ou de um sal farmaceuticamente aceitável ou um éster hidrolisável in vivo dos mesmos, composição farmacêutica, uso de um composto ou de um sal farmaceuticamente aceitável ou um éster hidrolisável in vivo dos mesmos, e, método para a produção de um efeito inibitório do ciclo celular (antiproliferação celular) em um animal de sangue quente
HUT56073A (en) Process for producing perhydroisoquinoline amino acid derivatives and pharmaceutical compositions comprising same
HU9201258D0 (en) Process for the production of medical preparations for treating hiv infections and of their active agents
KR910015562A (ko) 뇌부전 질환치료용 약제, 신규 2-(1-피페라지닐)-4-페닐시클로알카노 피리미딘 유도체, 및 그의 제법
NO159592C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolidinderivater.
ATE223916T1 (de) Kristalline pyrrolidylthiocarbapenem derivate, lyophilisierste präparationen dieser kristalle und verfahren zu deren herstellung
FI882605A (fi) Menetelmä, jonka avulla voidaan valmistaa suuren spesifisen tilavuusaktiivisuuden omaavaa liuosta proteiinista, jolla on kudosplasminogeeniaktivaattori(t-PA)-aktiivisuutta
ES2132135T3 (es) Procedimiento para la preparacion de compuestos de tiazolidina u oxazolidina farmaceuticamente activos mediante una reductasa de levadura.
ATE285770T1 (de) Verfahren zur herstellung von carbapenem- antibiotika zubereitungen
FI96424B (fi) Menetelmä kiteisten kefeemihappoadditiosuolojen valmistamiseksi
AU1022688A (en) Antibacterial lyophilized preparation
DE60127948D1 (de) Verfahren zur herstellung von avermectinderivaten
EP0153710A2 (de) Aus Pseudomonas aeruginosa stammende Elastase-Toxoide
ATE335494T1 (de) Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen
WO2002060475A1 (en) Methods for stabilizing lyophilized blood proteins
DE69429447T2 (de) Verwendung von 2-aminopurinderivaten zur behandlung und prophylaxe der menschlichen herpesvirus 7 infektionen
ATE210985T1 (de) Verwendung von 2-aminopurinderivaten zur behandlung und prophylaxe der menschlichen herpesvirus 6 infektionen
RU94031260A (ru) Питательная среда для выделения и культивирования гонококка
KR900014405A (ko) 세팔로스포린 유도체 및 이의 제조방법
TH9839A (th) อนุพันธ์โดโลเบนโซควิโนลีน,การเตรียมสารเหล่านั้นและการใช้สารเหล่าเป็นยาต่อต้านอาการหัวใจเต้นไม่ปกติ
TH9839EX (th) อนุพันธ์โดโลเบนโซควิโนลีน,การเตรียมสารเหล่านั้นและการใช้สารเหล่าเป็นยาต่อต้านอาการหัวใจเต้นไม่ปกติ
JPS6399022A (ja) 静脈内投与に適したガンマ・グロプリン
IL42863A (en) Polypeptides with protective and antibacterial properties

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties